Table 4 Univariate analysis of prognostic factors on recurrence-free and overall survival
| Â | Number of patient | 5-year recurrence-free survival (%) | P values | 5-year overall survival (%) | P values |
|---|---|---|---|---|---|
Overall | 159 | 20.8 | Â | 34.6 | Â |
| Â | Â | Â | Â | 39.6 | (from diagnosis of primary CRC) |
Gender | |||||
 Male | 89 | 19.5 | 0.699 | 31.5 | 0.449 |
 Female | 70 | 26.2 |  | 37.7 |  |
Location of the primary tumor(s) | |||||
 Transverse colon | 18 | 6.1 | 0.020 | 16.7 | 0.014 |
 Other area (inclusive of synchronous) | 141 | 24.4 |  | 36.4 |  |
Primary tumor staging | |||||
 T1, T2, or T3 | 71 | 29.0 | 0.057 | 42.9 | 0.017 |
 T4 | 88 | 17.3 |  | 27.3 |  |
Regional lymph node metastasis | |||||
 Negative | 32 | 41.7 | 0.002 | 48.4 | 0.004 |
 Positive | 127 | 17.7 |  | 30.7 |  |
Primary extrahepatic metastasis | |||||
 Negative | 141 | 25.1 | 0.000 | 37.9 | 0.000 |
 Positive | 18 | 0.0 |  | 5.6 |  |
Associated risky presentation(s) | |||||
 Negative | 138 | 23.5 | 0.424 | 38.0 | 0.047 |
 Positive | 21 | 15.1 |  | 9.5 |  |
Interval of liver metastasis | |||||
 Metachronous | 55 | 38.9 | 0.001 | 48.1 | 0.001 |
 Synchronous | 104 | 13.8 |  | 26.9 |  |
Involved hepatic segment(s) | |||||
 Single | 59 | 27.7 | 0.054 | 40.7 | 0.040 |
 Multiple | 100 | 19.3 |  | 30.3 |  |
Metastatic tumor distribution | |||||
 Unilobar | 114 | 24.1 | 0.193 | 37.2 | 0.200 |
 Bilobar | 45 | 18.2 |  | 26.7 |  |
Metastatic tumor location | |||||
 Peripherally located | 135 | 25.0 | 0.017 | 38.8 | 0.002 |
 Centrally located | 24 | 8.3 |  | 8.3 |  |
Maximal diameter of the largest metastasis | |||||
 <5 cm | 129 | 24.5 | 0.122 | 38.8 | 0.008 |
 ≥5 cm | 30 | 13.9 |  | 13.8 |  |
Number of liver metastasis | |||||
 Solitary | 101 | 30.0 | 0.000 | 40.6 | 0.001 |
 Multiple | 58 | 9.0 |  | 22.8 |  |
Differentiation of metastatic tumor | |||||
 Well differentiated | 15 | 43.1 | 0.219 (well vs. moderately) | 50.0 | 0.231 (well vs. moderately) |
 Moderately differentiated | 138 | 21.1 | 0.002 (moderately vs. poorly) | 34.1 | 0.000 (moderately vs. poorly) |
 Poorly differentiated | 6 | 0.0 | 0.004 (well vs. poorly) | 0.0 | 0.000 (well vs. poorly) |
Mucinous adenocarcinoma | |||||
 Yes | 13 | 23.1 | 0.813 | 38.5 | 0.922 |
 No | 146 | 22.4 |  | 33.8 |  |
Neoadjuvant chemotherapy for liver metastasis | |||||
 Yes | 15 | 20.0 | 0.677 | 35.7 | 0.477 |
 No | 144 | 22.8 |  | 20.0 |  |
Anatomic resection for liver metastasis | |||||
 Yes | 32 | 19.5 | 0.598 | 38.8 | 0.699 |
 No | 127 | 23.2 |  | 33.1 |  |
Resection margin of metastatic tumor | |||||
 ≥10 mm | 31 | 40.2 | 0.013 | 58.1 | 0.002 |
 <10 mm and involved | 128 | 18.2 |  | 28.4 |  |
Recurrence after liver resection | |||||
 Early recurrence (<4 months) | 33 |  |  | 0.0 | 0.000 |
 Late recurrence (≥4 months) | 89 |  |  | 24.7 |  |
 Involved organ(s) while recurrent | |||||
 Confined in liver, lung or both | 38 | 0.0 | 0.605 | 26.3 | 0.027 |
 Other distant organ(s) | 84 | 1.2 |  | 14.3 |  |